查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1806136

动物用药品市场按产品类型、动物种类、给药途径、疾病类型、最终用户和分销管道划分－2025-2030 年全球预测

Animal Pharmaceuticals Market by Product Type, Species, Route of Administration, Disease Type, End User, Distribution Channels - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年动物用药品市场价值将达到 418.9 亿美元，到 2025 年将成长至 457.4 亿美元，复合年增长率为 9.29%，到 2030 年将达到 714 亿美元。

主要市场统计数据
基准年2024年 418.9亿美元
预计2025年 457.4亿美元
预测年份 2030 714亿美元
复合年增长率（%） 9.29%

在全球健康需求和技术进步的背景下，为动物用药品策略成长奠定基础

全球动物用药品产业正处于关键的十字路口，消费者行为的转变、疾病光谱的演变以及技术突破共同重塑传统的市场动态。同时，伴侣动物照护也持续受益于宠物拥有量的增加和预防性治疗支出的增加。此外，人们对通用感染疾病传播的认识不断提高，这促使相关人员加快疫苗和诊断方法的研究，以保护动物和人类的健康。

了解推动全球兽医市场动物用药品开发和交付模式转移的因素

随着精准医疗、数位诊断和新型生技药品重新定义治疗模式，兽医医疗保健领域正在经历变革时期。包括次单位疫苗和减毒疫苗在内的先进疫苗平台展现出卓越的安全性和免疫抗原性，促使製造商重新评估传统方法。同时，远端医疗与基于感测器的监测技术的融合，实现了即时疾病监测，促进了早期疗育并降低了整体治疗成本。

评估2025年美国关税政策对动物用药品市场供应、定价压力和策略调整的多层影响

2025年，美国将对进口的关键动物用药品分阶段征收关税，这将给整个供应链带来新的成本压力，并迫使製造商重新评估其活性药物​​原料药筹资策略。抗生素、荷尔蒙和疫苗佐剂的供应商正面临利润压缩，迫使相关人员探索其他贸易伙伴关係和近岸外包选项。因此，国内製造能力正在透过产能投资和本地製造协议进行扩张，以缓解关税造成的价格波动。

探索跨产品、物种、管理、疾病、最终用户和渠道维度的策略性细分机会

详细的細項分析揭示了产品系列中的重要差异，麻醉剂和消炎药等传统类别与快速增长的生物疫苗和标靶驱虫药并存。抗生素仍发挥重要作用，但其种类日益多样化，反映了治疗应用的细微差别，包括Fluoroquinolones、大环内酯类、青霉素类、磺胺类药物和四环霉素。同时，驱虫药策略正在不断发展，以平衡广谱和专一性外寄生虫杀虫剂之间的疗效，灭活疫苗、减毒活病毒疫苗和次单位疫苗则在安全性、成本和免疫反应方面展开竞争。

绘製美洲、欧洲、中东和非洲地区以及亚太地区的区域动态，以扩大市场并客製化动物用药品解决方案

尤其是在北美，大规模畜牧养殖与成熟的伴侣动物市场共存。重要的是，区块链支援的可追溯性和整合低温运输物流等供应链创新正在提高透明度、减少腐败，并进一步提升市场效率。在拉丁美洲，酪农和牛肉产业的扩张正推动人们对经济高效的非专利药和社区疫苗接种倡议的兴趣。

分析动物保健产业的领先创新者，了解竞争定位、合作趋势和通路颠覆策略

动物用药品市场的领导地位体现在由行业巨头、专业化的中型企业和敏捷的生物技术公司组成的生态系统中。老字型大小企业正利用深厚的研发开发平臺，开发下一代疫苗、单株抗体和长效注射剂，以应对诸如抗生素抗药性和跨物种通用感染疾病威胁等紧迫挑战。同时，中型企业则专注于利润率较高的领域，例如马匹治疗、精准驱虫药和客製化营养补充剂，从而开拓利基市场。

产业领导者需要应对复杂的监管环境、利用技术进步并优化价值链的策略要务

产业领导者必须优先将数位健康工具整合到其全球商业化策略中。对远端医疗平台、感测器诊断和数据分析解决方案的投资，不仅可以改善治疗效果，还能创造差异化的服务，加深客户参与。此外，与生物技术新兴企业建立策略合作伙伴关係可以加速其获得基因编辑和合成生物学等创新平台的途径，使他们能够持续将颠覆性疗法引入其产品组合。

概述对全球动物用药品状况进行全面分析所采用的严格定性和定量方法

本分析基于严谨的调查方法，结合了定性和定量分析。主要研究包括对动物用药品製造商的高阶主管、监管专家、供应链经理和学术研究人员进行深入访谈。这些访谈提供了新兴趋势、策略重点和营运挑战的第一手观点。

综合关键见解，为不断发展的全球动物用药品生态系统中的相关人员提供指导

在本执行摘要中，我们探讨了重塑动物用药品产业的复杂因素，从不断变化的消费者需求和监管改革，到技术突破和地缘政治逆风。这些因素的交织凸显了相关人员采取灵活策略、利用创新并增强供应链韧性的必要性。市场领导者必须追求差异化的价值提案，同时对贸易政策和疾病模式演变所带来的成本压力保持警觉。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 单株抗体疗法在防治牲畜疾病的应用
  • 越来越多地采用行动兽医远端医疗平台进行远端动物健康管理
  • 开发抗生素替代品，例如噬菌体疗法，以对抗牲畜的抗生素抗药性
  • 为简化马匹和牛的疫苗接种计划，对联合疫苗通讯协定的需求不断增长
  • 实施基于区块链的可追溯系统以追踪动物医药分销和使用合规性
  • 基于人工智慧生物标记的精准给药技术的发展，优化了家禽的抗菌剂量
  • 扩大数位诊断，利用照护现场分子检测技术，早期检测伴侣动物的寄生虫

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第八章动物用药品市场（依产品类型）

  • 麻醉剂
  • 抗发炎药物
  • 抗生素
    • Fluoroquinolones
    • 大环内酯类
    • 青霉素
    • 磺胺类药物
    • 四环霉素
  • 荷尔蒙和生长调节剂
  • 杀寄生虫剂
    • 驱虫药
    • 杀外寄生虫剂
  • 疫苗
    • 灭活疫苗
    • 减毒活疫苗
    • 次单位疫苗

第九章动物用药品动物类型）

  • 水生动物
  • 鸟
  • 伴侣动物
    • 猫
    • 狗
    • 马
  • 家畜
    • 牛
    • 家禽
    • 绵羊和山羊
    • 猪
  • 野生动物

第十章动物用药品市场按管理途径

  • 口服
    • 胶囊
    • 液体溶液
    • 粉末
    • 药片
  • 注射药物
  • 外用
    • 奶油
    • 软膏
    • 喷

第十一章动物用药品市场（依疾病类型）

  • 感染疾病
    • 细菌感染疾病
    • 霉菌感染疾病
    • 寄生虫感染
    • 病毒感染
  • 非传染性疾病
    • 发炎性疾病
    • 代谢紊乱
    • 营养缺乏
    • 生殖障碍

第十二章动物用药品市场（依最终用户）

  • 政府和公共卫生机构
  • 牲畜和家禽养殖场
  • 宠物饲主
  • 研究机构
  • 兽医诊所和医院

第十三章动物用药品市场（依通路）

  • 线下药局
  • 网路药局

第 14 章：美洲动物用药品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 15 章：欧洲、中东和非洲动物用药品市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第 16 章：亚太动物用药品市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Aurora Pharmaceutical, Inc.
    • Biogenesis Bago SA
    • Biovac Ltd.
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Chanelle Pharma
    • China Animal Husbandry Industry Co., Ltd.
    • Dechra Pharmaceuticals PLC
    • ECO Animal Health Group PLC
    • Elanco Animal Health Incorporated
    • Hester Biosciences Limited
    • Huvepharma, Inc.
    • Indian Immunologicals Ltd.
    • Intas Pharmaceuticals Ltd.
    • Laboratorio Drag Pharma Chile Invetec SA
    • Merck & Co., Inc.
    • Neogen Corporation
    • Nippon Zenyaku Kogyo Co., Ltd.
    • Norbrook Group
    • Orion Corporation
    • PetIQ, LLC
    • Phibro Animal Health Corporation
    • Teknofarma Srl
    • Veterinary Pharmaceutical Solutions
    • Vetoquinol Group
    • Vetpharma Animal Health SL by Insud Pharma SLU
    • Virbac SA
    • Zendal Group
    • Zoetis Inc.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-434CCDA05128

The Animal Pharmaceuticals Market was valued at USD 41.89 billion in 2024 and is projected to grow to USD 45.74 billion in 2025, with a CAGR of 9.29%, reaching USD 71.40 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 41.89 billion
Estimated Year [2025] USD 45.74 billion
Forecast Year [2030] USD 71.40 billion
CAGR (%) 9.29%

Laying the Groundwork for Strategic Growth in Animal Pharmaceuticals Amidst Evolving Global Health Demands and Technological Advancements

The global animal pharmaceuticals sector stands at a pivotal juncture as shifting consumer behaviors, evolving disease profiles, and technological breakthroughs converge to reshape traditional market dynamics. Intensifying demand for high-quality protein sources in emerging economies is driving unprecedented investment in livestock health solutions, while companion animal care continues to benefit from rising pet ownership and increasing expenditures on preventive therapies. Furthermore, heightened awareness of zoonotic disease transmission is compelling stakeholders to accelerate research into vaccines and diagnostics that protect both animal and human health.

Amid these trends, regulatory agencies worldwide are streamlining approval pathways for innovative biologics, antimicrobial agents, and point-of-care diagnostics. Public-private partnerships are emerging to combat antimicrobial resistance, while venture capital initiatives are fueling startups to explore gene editing, precision dosing, and digital health platforms. These developments underscore the importance of a multi-faceted strategy that balances the need for rapid product development with stringent safety and efficacy standards.

Accordingly, industry leaders must ground their growth plans in robust market intelligence that captures complex value chains, evolving regulatory frameworks, and shifting epidemiological patterns. By aligning R&D pipelines with emerging customer needs and leveraging cross-sector collaborations, stakeholders can unlock sustainable growth and build resilience against future disruptions.

Uncovering the Forces Driving a Paradigm Shift in Animal Health Treatment Development and Delivery Across Global Veterinary Markets

The animal health landscape is witnessing transformative shifts as precision medicine, digital diagnostics, and novel biologics redefine treatment paradigms. Advanced vaccine platforms, including subunit and attenuated modalities, are demonstrating superior safety profiles and immunogenicity, driving manufacturers to re-evaluate traditional approaches. Meanwhile, the integration of telemedicine and sensor-based monitoring is enabling real-time disease surveillance, facilitating earlier intervention and reducing overall treatment costs.

Moreover, growing concerns around antimicrobial resistance have accelerated interest in alternative therapies such as phage therapy, probiotics, and host-directed immunomodulators. Companies are forging alliances with academic institutions to fast-track these innovations through collaborative research and pooled expertise. In parallel, artificial intelligence and machine learning models are being deployed to optimize dosage regimens and forecast disease outbreaks based on environmental and genetic risk factors.

Consequently, organizations that embrace these disruptive technologies while maintaining a strong focus on regulatory compliance and cost-effectiveness will be best positioned to capture emerging market segments. Building flexible supply networks and investing in agile manufacturing processes will further enable rapid scale-up of production, ensuring timely delivery of next-generation therapies to meet evolving veterinary needs.

Assessing the Layered Effects of 2025 US Tariff Policies on Supply, Pricing Pressure, and Strategic Realignment in the Animal Pharmaceuticals Market

In 2025, the imposition of layered US tariffs on key animal pharmaceutical imports has introduced new cost pressures throughout the supply chain, compelling manufacturers to reassess sourcing strategies for active pharmaceutical ingredients. Suppliers of antibiotics, hormones, and vaccine adjuvants have experienced margin compression, prompting stakeholders to explore alternative trade partnerships and near-shoring options. As a result, domestic production capabilities are being expanded through capacity investments and localized manufacturing agreements to mitigate tariff-induced price volatility.

Furthermore, higher import duties have led to downstream pricing adjustments that influence end-user purchasing behavior, with veterinary clinics and farms increasingly seeking value-based contracts and bundled service offerings. This shift is accelerating the adoption of generic formulations and biosimilars in regions where cost sensitivity remains high. At the same time, premium markets with strong veterinary infrastructure continue to exhibit willingness to pay for innovative biologics and advanced diagnostics.

Accordingly, agile supply chain management and proactive regulatory engagement are paramount. Organizations that secure diversified raw material sources, negotiate long-term procurement agreements, and establish in-country fill-finish capabilities will build resilience against future trade disruptions. Embracing digital supply chain visibility tools and advanced analytics will further empower decision-makers to respond swiftly to shifting tariff landscapes and maintain competitive pricing.

Delving into Product, Species, Administration, Disease, End User, and Channel Dimensions to Reveal Strategic Segmentation Opportunities

Deep segmentation analysis reveals critical differentiation within the product portfolio, where traditional categories such as anesthetics and anti-inflammatory medications coexist with fast-growing biologic vaccines and targeted parasiticides. Antibiotics maintain a prominent role but are increasingly stratified across fluoroquinolones, macrolides, penicillins, sulfonamides, and tetracyclines, reflecting nuanced therapeutic applications. At the same time, parasiticide strategies are evolving to balance efficacy between broad-spectrum anthelmintics and specialized ectoparasiticides, while inactivated vaccines, live attenuated vaccines, and subunit vaccines compete on the basis of safety, cost, and immune response.

Equally important is the species dimension, where treatments for aquatic animals, birds, companion animals such as cats, dogs, and horses, livestock including cattle, poultry, sheep and goats, and swine, as well as wild animal care, present unique pharmacological and delivery challenges. Route of administration further refines market opportunities, as oral solutions in capsules, liquids, powders, and tablets offer convenience but face bioavailability constraints, while parenteral interventions dominate acute care and topical formulations in creams, ointments, and sprays address localized conditions. Disease type segmentation divides interventions between infectious diseases, encompassing bacterial, fungal, parasitic, and viral infections, and non-infectious disorders that range from inflammatory diseases to metabolic, nutritional, and reproductive disorders. End-user profiles complete the landscape, where government and public health bodies, livestock and poultry farms, pet owners, research institutions, and veterinary clinics and hospitals each demonstrate distinct procurement criteria. Finally, the channel dimension highlights the rising influence of online pharmacies alongside established offline pharmacy networks, signaling a shift in distribution strategies.

Mapping Regional Dynamics in Americas, EMEA, and Asia-Pacific to Guide Market Expansion and Tailored Veterinary Health Solutions

Regional dynamics in the Americas continue to be shaped by robust research infrastructure, well-defined regulatory pathways, and high per-animal expenditure, particularly in North America where large-scale livestock operations and sophisticated companion animal markets coexist. Importantly, supply chain innovations such as blockchain-enabled traceability and integrated cold-chain logistics are enhancing transparency and reducing spoilage, further bolstering market efficiency. In Latin America, expanding dairy and beef industries are driving interest in cost-effective generic therapeutics and community vaccination initiatives.

Across Europe, Middle East, and Africa, heterogeneous regulatory frameworks present both challenges and opportunities. EU member states emphasize stringent safety and environmental standards, spurring investment in next-generation biologics and antimicrobial stewardship programs. Meanwhile, Middle Eastern markets are witnessing an uptick in private veterinary services and demand for premium companion animal products. In Africa, emerging economies are prioritizing zoonotic disease control through public health campaigns and donor-funded vaccine distribution, highlighting the need for low-cost, thermostable formulations.

Asia-Pacific stands out for its dual landscape of rapidly modernizing production hubs and diverse disease burdens. Countries with advanced manufacturing capacity, such as Japan and South Korea, continue to lead innovation in precision biologics, while China and India are scaling up generic production to serve domestic and export markets. Southeast Asian nations are increasingly focused on aquaculture health solutions, reflecting the region's significant contribution to global fish protein supply. These varied regional profiles underscore the importance of tailored market entry and product strategies.

Profiling Leading Animal Health Innovators to Understand Competitive Positioning, Collaborative Trends, and Pipeline Disruption Strategies

Market leadership in animal pharmaceuticals is characterized by an ecosystem of industry giants, specialized mid-tier players, and agile biotechnology firms. Established corporations are leveraging their deep R&D pipelines to advance next-generation vaccines, monoclonal antibodies, and long-acting injectables that address pressing challenges such as antimicrobial resistance and cross-species zoonotic threats. Meanwhile, mid-sized companies are carving out niche positions by focusing on high-margin segments such as equine therapeutics, precision parasiticides, and bespoke nutritional supplements.

Collaborative partnerships are reshaping the competitive landscape, as alliances between multinational firms and academic spin-offs accelerate translational research. Licensing agreements for proprietary adjuvants and novel delivery technologies are becoming increasingly common, enabling smaller innovators to scale their solutions through established global networks. In addition, strategic M&A activity highlights a trend toward consolidating complementary capabilities, with acquirers seeking to bolster biologics platforms and digital health offerings. These moves are redefining traditional market hierarchies and setting new benchmarks for value creation.

Strategic Imperatives for Industry Leaders to Navigate Regulatory Complexity, Leverage Technological Advances, and Optimize Value Chains

Industry leaders must prioritize the integration of digital health tools into their global commercialization strategies. Investing in telemedicine platforms, sensor-enabled diagnostics, and data analytics solutions will not only enhance treatment outcomes but also create differentiated service offerings that deepen customer engagement. Furthermore, forging strategic alliances with biotechnology startups can accelerate access to innovative platforms such as gene editing and synthetic biology, ensuring a continuous flow of disruptive therapies into the portfolio.

Regulatory engagement should be elevated from a compliance function to a proactive strategic capability. By participating in policy dialogues, contributing to antimicrobial stewardship guidelines, and advocating for harmonized approval pathways, organizations can shape favorable environments for advanced biologics and novel modalities. Finally, building supply chain resilience through diversified sourcing, in-country manufacturing partnerships, and digital traceability systems will safeguard against future trade disruptions and strengthen market responsiveness.

Outlining Rigorous Qualitative and Quantitative Approaches Underpinning Comprehensive Analysis of the Global Animal Pharmaceuticals Landscape

This analysis is founded on a rigorous research methodology that integrates both qualitative and quantitative approaches. Primary research included in-depth interviews with senior executives at veterinary pharmaceutical manufacturers, regulatory experts, supply chain managers, and academic researchers. These conversations provided firsthand perspectives on emerging trends, strategic priorities, and operational challenges.

Secondary research encompassed an exhaustive review of scientific literature, regulatory filings, patent databases, and industry publications. Market dynamics were further validated through proprietary data sets and trade statistics, while competitive landscapes were mapped using detailed product registries and company disclosures. All data points underwent cross-verification to ensure accuracy and relevance, and insights were synthesized through collaborative workshops with subject-matter experts. This robust methodology underpins the credibility and depth of our findings.

Synthesizing Critical Findings to Chart a Path Forward for Stakeholders in the Evolving Global Veterinary Pharmaceuticals Ecosystem

Throughout this executive summary, we have navigated the intricate forces reshaping the animal pharmaceuticals industry, from shifting consumer demands and regulatory reforms to technological breakthroughs and geopolitical headwinds. The convergence of these factors underscores the necessity for stakeholders to adopt agile strategies, harness emerging innovations, and strengthen supply chain resilience. As market leaders pursue differentiated value propositions, they must remain vigilant to cost pressures introduced by trade policies and evolving disease patterns.

Looking ahead, sustained growth will depend on the ability to balance investment across core segments such as antibiotics, vaccines, and parasiticides while exploring frontier areas including precision biologics, digital health, and alternative therapeutics. By embedding a culture of continuous innovation and proactive collaboration, organizations can position themselves to meet the complex health needs of diverse animal populations and drive sustainable value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Use of monoclonal antibody therapies for livestock disease prevention and treatment
  • 5.2. Increasing adoption of mobile veterinary telemedicine platforms for remote animal health management
  • 5.3. Development of antibiotic alternatives such as bacteriophage therapies to combat antimicrobial resistance in farm animals
  • 5.4. Rising demand for combination vaccine protocols to streamline immunization schedules in equine and cattle herds
  • 5.5. Implementation of blockchain-based traceability systems for tracking veterinary drug distribution and usage compliance
  • 5.6. Growth of precision dosing technologies using ai-enabled biomarkers for optimized antimicrobial administration in poultry
  • 5.7. Expansion of parasitic digital diagnostics using point-of-care molecular assays for early detection in companion animals

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Animal Pharmaceuticals Market, by Product Type

  • 8.1. Introduction
  • 8.2. Anesthetics
  • 8.3. Anti-Inflammatory Medications
  • 8.4. Antibiotics
    • 8.4.1. Fluoroquinolones
    • 8.4.2. Macrolides
    • 8.4.3. Penicillins
    • 8.4.4. Sulfonamides
    • 8.4.5. Tetracyclines
  • 8.5. Hormones & Growth Regulators
  • 8.6. Parasiticides
    • 8.6.1. Anthelmintics
    • 8.6.2. Ectoparasiticides
  • 8.7. Vaccines
    • 8.7.1. Inactivated Vaccines
    • 8.7.2. Live Attenuated Vaccines
    • 8.7.3. Subunit Vaccines

9. Animal Pharmaceuticals Market, by Species

  • 9.1. Introduction
  • 9.2. Aquatic Animals
  • 9.3. Birds
  • 9.4. Companion Animals
    • 9.4.1. Cats
    • 9.4.2. Dogs
    • 9.4.3. Horses
  • 9.5. Livestock Animals
    • 9.5.1. Cattle
    • 9.5.2. Poultry
    • 9.5.3. Sheep & Goats
    • 9.5.4. Swine
  • 9.6. Wild Animals

10. Animal Pharmaceuticals Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Liquid solutions
    • 10.2.3. Powders
    • 10.2.4. Tablets
  • 10.3. Parenteral
  • 10.4. Topical
    • 10.4.1. Creams
    • 10.4.2. Ointments
    • 10.4.3. Sprays

11. Animal Pharmaceuticals Market, by Disease Type

  • 11.1. Introduction
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Parasitic Infestations
    • 11.2.4. Viral Infections
  • 11.3. Non-Infectious Diseases
    • 11.3.1. Inflammatory Diseases
    • 11.3.2. Metabolic Disorders
    • 11.3.3. Nutritional Deficiencies
    • 11.3.4. Reproductive Disorders

12. Animal Pharmaceuticals Market, by End User

  • 12.1. Introduction
  • 12.2. Government & Public Health Organizations
  • 12.3. Livestock Farms & Poultry Farms
  • 12.4. Pet Owners
  • 12.5. Research Institutions
  • 12.6. Veterinary Clinics & Hospitals

13. Animal Pharmaceuticals Market, by Distribution Channels

  • 13.1. Introduction
  • 13.2. Offline Pharmacies
  • 13.3. Online Pharmacies

14. Americas Animal Pharmaceuticals Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Animal Pharmaceuticals Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Animal Pharmaceuticals Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Aurora Pharmaceutical, Inc.
    • 17.3.2. Biogenesis Bago S.A.
    • 17.3.3. Biovac Ltd.
    • 17.3.4. Boehringer Ingelheim International GmbH
    • 17.3.5. Ceva Sante Animale
    • 17.3.6. Chanelle Pharma
    • 17.3.7. China Animal Husbandry Industry Co., Ltd.
    • 17.3.8. Dechra Pharmaceuticals PLC
    • 17.3.9. ECO Animal Health Group PLC
    • 17.3.10. Elanco Animal Health Incorporated
    • 17.3.11. Hester Biosciences Limited
    • 17.3.12. Huvepharma, Inc.
    • 17.3.13. Indian Immunologicals Ltd.
    • 17.3.14. Intas Pharmaceuticals Ltd.
    • 17.3.15. Laboratorio Drag Pharma Chile Invetec S.A.
    • 17.3.16. Merck & Co., Inc.
    • 17.3.17. Neogen Corporation
    • 17.3.18. Nippon Zenyaku Kogyo Co., Ltd.
    • 17.3.19. Norbrook Group
    • 17.3.20. Orion Corporation
    • 17.3.21. PetIQ, LLC
    • 17.3.22. Phibro Animal Health Corporation
    • 17.3.23. Teknofarma S.r.l.
    • 17.3.24. Veterinary Pharmaceutical Solutions
    • 17.3.25. Vetoquinol Group
    • 17.3.26. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
    • 17.3.27. Virbac S.A.
    • 17.3.28. Zendal Group
    • 17.3.29. Zoetis Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. ANIMAL PHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. ANIMAL PHARMACEUTICALS MARKET: RESEARCHAI
  • FIGURE 28. ANIMAL PHARMACEUTICALS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. ANIMAL PHARMACEUTICALS MARKET: RESEARCHCONTACTS
  • FIGURE 30. ANIMAL PHARMACEUTICALS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ANIMAL PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 173. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 175. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 213. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 216. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 217. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 218. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 219. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 221. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 223. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 225. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 227. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 229. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 231. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 232. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 233. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 236. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 237. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 238. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 239. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 241. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 243. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 246. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 247. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 249. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 251. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 253. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 255. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 256. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 257. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 259. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 261. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 263. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 267. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 269. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 273. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 277. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 279. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 281. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 283. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 285. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 287. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 289. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 290. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 291. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 293. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 296. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 297. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 299. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 301. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 302. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 303. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 306. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 307. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 308. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 309. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 310. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 311. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 312. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 313. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 314. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 315. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 316. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 317. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 319. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 320. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 321. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 322. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 323. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 325. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)

TABL